Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Changing Paradigms In Hereditary Angioedema: A Focus On Timely Diagnosis And New Therapies
Hereditary angioedema (HAE) is an autosomal dominant disease affecting approximately 10,000 people in the United States. HAE causes recurrent attacks of intense localized edema involving the skin, airway, and visceral organs. While chronic therapy with attenuated androgens or plasmin inhibitors has been the mainstay of HAE therapy, many new therapies for prophylaxis and acute treatment are on the horizon. It is important for physicians to understand the signs and symptoms of patients who present with HAE and to be familiar with the conventional and emerging therapies available to treat them.
generic viagra online
2009/039 NICE Guidance Recommends Lenalidomide For Multiple Myeloma
The National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of lenalidomide for multiple myeloma in people who have received at least one prior therapy.
News of the day
Prevention Magazine™ Says "Take SunPill To Boost UV Sun Protection"
XenaCare Holdings Inc. (OTCBB:XCHO), a healthcare company specializing in the branding, retailing and internet distribution of consumer products, has announced today that in the July 2009 issue of Prevention Magazine™ an article written by Roopoka Malhorta which is about Ageless Summer Beauty - 21 fast, easy ways to look young - and stay that way - this summer and beyond states as their #1 choice was to "Try a Sun Protection pill" they further stated "ò€¦boost your UV protection by taking an antioxidant supplement such as SunPill ($20 for a month"s supply; available at http://www.sunpill.com)." According to Frank Rizzo, president of XenaCare, the SunPill can also be purchased at Walgreens, Rite-Aid, Amazon.com, Drugstore.com, CVS.com, Target.com and various other major retailers.
Sexual Health

The Evolution Of Migraine From Episodic Headache To Chronic Disorder

Patients living with migraine have strong reason for new optimism concerning a positive future. Two review articles and an accompanying editorial, "The Future of Migraine: Beyond Just Another Pill," in the current issue of Mayo Clinic Proceedings, are the basis for an ironic premise. "Migraine is a potentially chronic, progressive disease that substantially affects patients, families, workplaces, and society," according to the editorial written by Roger Cady, M.D., of the Headache Care Center in Springfield, Mo. "Ironically, this is the springboard for renewed optimism of a more positive future for patients living with migraine." Traditionally, Dr. Cady explains, migraine has been considered a pain disorder involving separate or even sporadic episodes. Now, the condition is defined as an all-encompassing and progressive disease that negatively affects all aspects of an individual"s life. Migraine can erode quality of life during what should be a person"s most productive years, according to Dr. Cady. Because migraine patients" quality of life has not improved at a pace with medical advances, research is addressing the overall severity and potential progressive nature of migraine, especially migraine episodes as a forerunner of chronic migraine. According to the three articles, these new insights and understandings are requiring professionals to explore well beyond traditional migraine management. "Understanding migraine as a potentially chronic disease mandates a collaborative health care model with patients and health care professionals working in a partnership toward common therapeutic goals," writes Dr. Cady, specifically intervention and prevention. Physicians and patients must be encouraged to be partners, he says, and evaluation must go far beyond the physician just asking, "How are your migraines?" The models must include an invitation to comprehend and address all migraine-related health issues facing patients, Dr. Cady writes. In addition, understanding the evolutionary "stages" of migraine from sporadic to persistent offers an opportunity to develop new therapies that individualize and personalize care. In the future, successful management of migraine will ideally be measured not by stopping an attack but by overall disease management and prevention, according to the researchers. This new understanding of migraine as a chronic disease offers many challenges and rewards, according to Dr. Cady. "Today, the focus of care is rapidly changing from the event of the migraine to the patient with migraine," he notes. These changes present great promise for patients and health care professionals alike, representing assurances of a better future for patients with migraine, concludes Dr. Cady. John Murphy Mayo Clinic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009